Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia A total of 1,560 ...

Please provide your email address to receive an email when new articles are posted on . Adding hyperthermic intraperitoneal chemotherapy to cytoreductive surgery did not significantly prolong PFS or ...

Cancers originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and liver) account for approximately 250,000 new cancer cases annually in the USA. Peritoneal ...

Because cytotoxicity is one of the major hurdles in the application of many transfection agents, an important feature of our cationic liposome is its low toxicity for cells at the concentrations ...

HIPEC surgery is a promising treatment option for patients with certain abdominal cancers. Surgical oncologist Erin Ward, MD, discusses which patients would be best candidates for HIPEC, explains why ...

(HealthDay)—Intraperitoneal (IP) chemotherapy is associated with improved survival in advanced ovarian cancer compared with standard intravenous (IV) therapy, according to a study presented at the ...

VS-01 is a novel liposomal-based intraperitoneal fluid that acts as a clearance enhancer of toxic metabolites, in particular ammonia, from the body. The Food and Drug Administration (FDA) has granted ...

Another major limitation of IP therapy is the lack of efficacy in larger, bulky tumors. In ovarian cancer, the postsurgical residual tumor size is the most significant prognostic indicator for IP ...